Cenomate 50mg

Phenytoin: Gradually decrease phenytoin dosage by up to 50%

Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with Cenomate.

Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with Cenomate.

CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with Cenomate.

CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with Cenomate.

Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with Cenomate. Women should use additional or alternative non-hormonal birth control

Cenobamate is contraindicated in patients with a known-

• Hypersensitivity to either Cenobamate or to any excipients in Cenobamate.
• Familial Short QT syndrome

Common: Somnolence, fatigue, dizziness or feeling sleepy, nausea, constipation, double vision, decreased appetite, diarrhea, or weakness may occur.

Rare: A very serious allergic reaction to Cenomate is rare.

There are no adequate and well-controlled studies in pregnant women with the use of Cenobamate. But it may cause fetal harm when administered to a pregnant woman. It should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. There are no data on the presence of Cenobamate in human milk, the effects of Cenobamate on the breastfed infant, or the effects of Cenobamate on milk production.

Potential adverse effects such as Multiorgan hypersensitivity reaction, QT shortening, and Suicidal thoughts. Somnolence and fatigue should be periodically re-evaluated. During Cenomate therapeutic regimen, patients are advised not to drive or operate machinery. Cenomate should be gradually withdrawn to minimize the potential or increased seizure frequency.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) / Multi-Organ Hypersensitivity: Discontinue if no alternate etiology.

QT Shortening: Use caution when administering Cenomate with other drugs that shorten the QT interval

Suicidal Behavior and Ideation: Monitor patients for suicidal behavior and ideation.

Neurological Adverse Reactions: Monitor for somnolence and fatigue and advise patients not to drive or operate machinery until they have gained sufficient experience on Cenomate. Concomitant use with other CNS depressants or alcohol may have additive effects.

Withdrawal of Antiepileptic Drugs: Cenomate should be gradually withdrawn to minimize the potential of increased seizure frequency

Pediatric use: The safety and efficacy of Cenomate in children under 18 years have not yet been established.

Geriatric use: Start at the low end of the dosing range.

Renal impairment: Cenomate should be used with caution and reduction of the target dose may be considered in patients with mild to moderate (creatinine clearance 30 to <90 ml/min) or severe (creatinine clearance <30 ml/min) renal impairment. The maximum recommended dose for patients with mild, moderate, or severe renal impairment is 300 mg/day. Cenomate should not be used in patients with end-stage renal disease or patients undergoing hemodialysis.

Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment: lower maximum dose and additional dose reduction may be considered. The use of Cenomate in patients with severe hepatic impairment is not recommended.

In the event of overdose, Cenomate should be discontinued and general supportive treatment given until clinical toxicity has been diminished or resolved.